Oligonucleotide Therapeutics and Delivery Conference 2022

Date: 21st – 22nd September 2022

Location: London, UK

Website: http://www.oligonucleotide.co.uk/BioPharmaTrend

Advancements in extra-hepatic delivery of oligonucleotides

The Oligonucleotide Therapeutics and Delivery conference reveals the latest in oligonucleotide discovery and delivery, with presentations on targeted delivery mechanisms, oligonucleotide chemistries and important clinical advances. Global experts from big pharma and leading biotechs will explore the emerging therapeutic applications of oligonucleotides with case studies surrounding the discovery and development of oligonucleotide therapeutics as well as CMC and regulatory standpoints. The two-day conference will bring you high-quality insights and industry connections on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY.

Established on the success of our RNA Therapeutics series, we look forward to welcoming you at Oligonucleotide Therapeutics and Delivery to join the conversation around maximizing the potential of oligo-based treatments.

Benefits of attending:

Listen to case studies presenting on pre-clinical and clinical research in areas such as oncology and what can be learned for future clinical trials
Deepen your understanding of oligonucleotide therapeutic delivery and explore the latest innovations in extrahepatic oligonucleotide delivery and target specificity
Understand the regulatory and CMC environment surrounding oligonucleotide therapeutic development
Explore developments in oligonucleotide chemistries and examine developments in novel applications of antisense oligonucleotides and siRNA
Engage in the latest innovations in oligonucleotide therapeutics such as utilising AI machine learning to drive the discovery of novel therapeutics

Plus, two interactive half day pre-conference workshops on 20th September 2022:

Oligonucleotide Therapies- Overcoming The Challenges Of Delivery led by Nick Lench, Executive Director, NATA, Martin Kerr, Head of Business Development & Partnerships, Nucleic Acid Therapy Accelerator, Ritwick Sawakar, MRC Investigator, MRC Toxcology Unit, University Of Cambridge
Managing CMC Activities For The Development Of Oligonucleotide Therapeutics led by Mia Kiistala, CEO/Owner/Principal Consultant, Aurora CMC Consulting

CHAIRS FOR 2022:

Ekkehard Leberer, Senior Life Sciences Consultant, Elbicon
Jimmy Weterings, Principal Scientist, AstraZeneca

FEATURED 2022 SPEAKERS INCLUDE:

Shalini Anderson, Vice President Oligonucleotide Discovery,AstraZeneca
Heinrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech
Tamar Grossman, Global Head of RNA and Targeted Therapeutics, Janssen pharmaceuticals
Sarah Tabrizi, Director of UCL Huntington’s disease centre, UCL Institute of Neurology
Macarena Hernandez-Jimenez, Chief Scientific Officer, AptaTargets
David Evans, Chief Scientific Officer, Sirnaomics
Eric Lim, Director, Platform, Discover Research, Stoke Therapeutics, Inc.
Chris Chorley, Associate Director, Global Regulatory CMC, Biogen
Oliver Ernst, Managing Director, Chief Operating Officer, Neuway Pharma GmbH
Nick Lench, Executive Director, Nucleic Acid Therapy Accelerator
Bart Anderson, Senior Director of R&D, Exicure